Reference-Standard Material Qualification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reference-Standard Material Qualification
The author reviews the types of reference-standard materials used in drug-product manufacturing, discusses current regulatory requirements, and outlines a reference-standard qualification program.


Pharmaceutical Technology
Volume 33, Issue 4, pp. 66-73

Regulatory requirements

The integrity of reference standards must be proven for products that are used in registration applications, commercial releases, stability studies, or pharmacokinetic studies. FDA requires reference standards to be of the "highest purity that can be obtained through reasonable effort" and to be "thoroughly characterized to assure the identity, strength, and quality" (3). This requirement is meant to ensure that the product being evaluated is accurately tested to determine the amount of API present and to classify and identify related substances, process-related impurities, and degradation products.

To fully understand the development of a reference-standard material program, the required method validation needs to be discussed. FDA requires noncompendial reference standards to be "of the highest purity" and asks that reference standards validate analytical methods (1). This raises the question, Which requirement should be met first: the qualification of the reference standard or its method validation? The answer is a compromise based on suitable parameters for the intended application.

Quantitative analytical procedures for impurities' content or limit tests for the control of impurities must be validated and suitable for the detection and quantitation of impurities as directed by the International Conference on Harmonization (ICH) (6). FDA cites "failure to submit well characterized reference standards" as a "common problem that can delay successful validation" (3). An insufficiently characterized reference standard may delay or prevent FDA approval of a drug product to market.

To ascertain the degree to which an analytical method is deemed suitable for its intended use, the validation parameters set forth in ICH Q2(R1) Validation of Analytical Procedures (6) stipulates the following criteria:

  • Specificity—evaluation of interference from extraneous components
  • Linearity—linear range of the method
  • Range—the interval between the lower and upper concentration amounts of analyte in the sample
  • Accuracy—a measure of the closeness of agreement between the value obtained and the theoretical
  • Precision—a measure of the closeness of agreement (degree of scatter) of the data values over a number of measurements (i.e., injection repeatability, analysis repeatability (multiple measurements, same analyst) and intermediate precision (multiple measurements, different days, different analysts), reproducibility (precision between different labs)
  • Detection limit—the lowest level the analyte can be detected
  • Quantitation limit—the lowest level the analyte can be quantitated
  • Robustness—effects of small changes in method parameters
  • System suitability testing—evaluation of the suitability of the equipment.


Table I: Types of reference-standard material compared with recommended qualification.
Not all parameters can be evaluated because a reference standard is required to perform quantitation. In this case, where the reference standard is the sample, the parameters validated are restricted. However, the method can be assessed for parameters applicable to evaluating the reference material. The analytical method is therefore qualified for use but not validated per ICH guidelines. Table I presents recommended qualification parameters compared with reference-standard material type. ICH also requires the reference material to be proven stable under the intended storage conditions for the intended use period (7). The reference-standard material program, therefore, must be designed so that the material is assessed at its intended storage condition over time.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here